Kairos Pharma, LTD. — Form 8-K
Filed August 21, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Kairos Pharma's board and shareholders approved a 1-for-7 reverse stock split effective September 1, 2026 at 12:01 a.m. ET. Every 7 shares of common stock will combine into 1 share; fractional shares round up to the nearest whole share. The split aims to increase per-share trading price and maintain NYSE American listing compliance. All security conversion rates (convertible notes, warrants, equity awards) will be proportionately adjusted; stockholders' percentage ownership and voting power remain unchanged except for minor fractional-share effects.
Why this rating
Reverse split is routine capital-structure housekeeping for micro-cap ($6.9M) struggling with listing compliance. No material business change; cosmetic per-share price increase does not alter fundamentals.
See more from August 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.